| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 66 | 2023 | 1721 | 10.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 21 | 2020 | 173 | 3.810 |
Why?
|
| Androgen Antagonists | 18 | 2022 | 144 | 3.310 |
Why?
|
| Radiation Injuries | 9 | 2019 | 156 | 3.300 |
Why?
|
| Prostatectomy | 24 | 2022 | 471 | 2.960 |
Why?
|
| Adenocarcinoma | 17 | 2019 | 1168 | 2.840 |
Why?
|
| Prostate-Specific Antigen | 24 | 2022 | 353 | 2.770 |
Why?
|
| Chemoradiotherapy | 7 | 2021 | 301 | 2.710 |
Why?
|
| Radiotherapy Dosage | 28 | 2023 | 468 | 2.570 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2022 | 1313 | 2.240 |
Why?
|
| Anus Neoplasms | 4 | 2021 | 30 | 2.060 |
Why?
|
| Radiotherapy, Conformal | 7 | 2016 | 83 | 1.960 |
Why?
|
| Salvage Therapy | 16 | 2022 | 233 | 1.920 |
Why?
|
| Urinary Incontinence | 4 | 2016 | 206 | 1.670 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2018 | 292 | 1.660 |
Why?
|
| Anticoagulants | 5 | 2022 | 406 | 1.650 |
Why?
|
| Quality of Life | 7 | 2022 | 1581 | 1.620 |
Why?
|
| Aged | 61 | 2024 | 18161 | 1.610 |
Why?
|
| Male | 92 | 2023 | 40652 | 1.570 |
Why?
|
| Aged, 80 and over | 34 | 2020 | 6479 | 1.500 |
Why?
|
| Middle Aged | 64 | 2020 | 24740 | 1.470 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2024 | 383 | 1.370 |
Why?
|
| Prostate | 7 | 2023 | 378 | 1.310 |
Why?
|
| Radiotherapy, Image-Guided | 5 | 2020 | 56 | 1.300 |
Why?
|
| Humans | 110 | 2024 | 85777 | 1.240 |
Why?
|
| Brachytherapy | 8 | 2019 | 119 | 1.220 |
Why?
|
| Head and Neck Neoplasms | 6 | 2021 | 1052 | 1.200 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2021 | 150 | 1.200 |
Why?
|
| Neoplasm Staging | 22 | 2020 | 1938 | 1.170 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 239 | 1.150 |
Why?
|
| Follow-Up Studies | 20 | 2022 | 3591 | 1.090 |
Why?
|
| Radiotherapy | 9 | 2019 | 328 | 1.070 |
Why?
|
| Urogenital System | 4 | 2014 | 9 | 1.060 |
Why?
|
| Fluorouracil | 7 | 2017 | 555 | 1.050 |
Why?
|
| Radiosurgery | 4 | 2019 | 272 | 1.050 |
Why?
|
| Capecitabine | 5 | 2024 | 96 | 1.020 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2022 | 133 | 0.960 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 386 | 0.950 |
Why?
|
| Rectal Neoplasms | 4 | 2016 | 116 | 0.910 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 737 | 0.910 |
Why?
|
| Rectal Diseases | 3 | 2013 | 24 | 0.900 |
Why?
|
| Combined Modality Therapy | 20 | 2024 | 1677 | 0.880 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2018 | 236 | 0.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2018 | 2438 | 0.860 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 173 | 0.860 |
Why?
|
| Pancreatic Neoplasms | 4 | 2017 | 645 | 0.820 |
Why?
|
| Aspirin | 2 | 2013 | 153 | 0.800 |
Why?
|
| Treatment Outcome | 24 | 2020 | 7830 | 0.800 |
Why?
|
| Radiation Oncology | 4 | 2021 | 119 | 0.800 |
Why?
|
| Gastrointestinal Tract | 3 | 2013 | 190 | 0.790 |
Why?
|
| Patient Care Team | 1 | 2023 | 280 | 0.790 |
Why?
|
| Risk Assessment | 12 | 2020 | 2213 | 0.770 |
Why?
|
| Urinary Bladder | 3 | 2024 | 245 | 0.750 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2017 | 35 | 0.750 |
Why?
|
| Hypersensitivity | 1 | 2022 | 154 | 0.740 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2018 | 1076 | 0.720 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 118 | 0.710 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 3366 | 0.700 |
Why?
|
| Retrospective Studies | 24 | 2021 | 8456 | 0.700 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 6 | 0.700 |
Why?
|
| Cystectomy | 3 | 2024 | 102 | 0.700 |
Why?
|
| Fiducial Markers | 2 | 2020 | 7 | 0.690 |
Why?
|
| Rectum | 4 | 2014 | 146 | 0.690 |
Why?
|
| Analysis of Variance | 9 | 2015 | 901 | 0.680 |
Why?
|
| Neoplasm Grading | 9 | 2022 | 357 | 0.670 |
Why?
|
| Hematuria | 3 | 2022 | 48 | 0.670 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 217 | 0.670 |
Why?
|
| Prognosis | 15 | 2020 | 3639 | 0.650 |
Why?
|
| Adult | 32 | 2020 | 25518 | 0.630 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2583 | 0.620 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 77 | 0.620 |
Why?
|
| Time Factors | 15 | 2020 | 5178 | 0.600 |
Why?
|
| Organs at Risk | 3 | 2020 | 41 | 0.570 |
Why?
|
| Leukopenia | 1 | 2016 | 65 | 0.570 |
Why?
|
| Organ Transplantation | 1 | 2020 | 265 | 0.570 |
Why?
|
| Pelvic Bones | 1 | 2016 | 43 | 0.560 |
Why?
|
| Prospective Studies | 8 | 2022 | 4160 | 0.560 |
Why?
|
| Risk Factors | 10 | 2020 | 5249 | 0.550 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2015 | 468 | 0.550 |
Why?
|
| Biomarkers, Tumor | 3 | 2012 | 1465 | 0.530 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 183 | 0.530 |
Why?
|
| Cohort Studies | 8 | 2022 | 2738 | 0.520 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 977 | 0.510 |
Why?
|
| Bone Marrow | 1 | 2016 | 435 | 0.510 |
Why?
|
| Sexuality | 1 | 2014 | 40 | 0.490 |
Why?
|
| Tumor Burden | 5 | 2019 | 290 | 0.490 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 985 | 0.480 |
Why?
|
| Survival Rate | 9 | 2019 | 1849 | 0.460 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2013 | 230 | 0.450 |
Why?
|
| Urinary Retention | 2 | 2010 | 39 | 0.450 |
Why?
|
| Transurethral Resection of Prostate | 2 | 2010 | 9 | 0.450 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 2360 | 0.440 |
Why?
|
| Hospitalization | 1 | 2018 | 830 | 0.440 |
Why?
|
| CA-19-9 Antigen | 1 | 2012 | 11 | 0.440 |
Why?
|
| SEER Program | 6 | 2020 | 190 | 0.440 |
Why?
|
| Herpes Zoster | 1 | 2013 | 78 | 0.430 |
Why?
|
| Postoperative Complications | 2 | 2020 | 2202 | 0.430 |
Why?
|
| Neoadjuvant Therapy | 2 | 2012 | 318 | 0.430 |
Why?
|
| Chemoprevention | 1 | 2012 | 92 | 0.420 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 41 | 0.420 |
Why?
|
| Portal Vein | 1 | 2012 | 119 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2017 | 850 | 0.410 |
Why?
|
| Diabetes Complications | 1 | 2013 | 170 | 0.410 |
Why?
|
| Lymphatic Metastasis | 5 | 2017 | 486 | 0.400 |
Why?
|
| Risk | 4 | 2020 | 657 | 0.400 |
Why?
|
| Radioimmunodetection | 2 | 2008 | 13 | 0.390 |
Why?
|
| Deoxycytidine | 2 | 2012 | 237 | 0.390 |
Why?
|
| Female | 25 | 2022 | 44216 | 0.380 |
Why?
|
| Prostatism | 1 | 2010 | 5 | 0.380 |
Why?
|
| Lymph Nodes | 3 | 2020 | 533 | 0.370 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 106 | 0.370 |
Why?
|
| Urination Disorders | 1 | 2010 | 50 | 0.370 |
Why?
|
| Body Burden | 1 | 2009 | 9 | 0.360 |
Why?
|
| Withholding Treatment | 1 | 2010 | 112 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 992 | 0.350 |
Why?
|
| Venous Thrombosis | 1 | 2012 | 243 | 0.350 |
Why?
|
| Smoking | 1 | 2013 | 604 | 0.340 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2016 | 188 | 0.340 |
Why?
|
| Survival Analysis | 9 | 2019 | 1532 | 0.330 |
Why?
|
| Models, Statistical | 1 | 2012 | 574 | 0.330 |
Why?
|
| Leucovorin | 3 | 2017 | 218 | 0.330 |
Why?
|
| Comorbidity | 3 | 2021 | 912 | 0.320 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2019 | 424 | 0.310 |
Why?
|
| Hemorrhage | 1 | 2009 | 267 | 0.300 |
Why?
|
| Disease Progression | 3 | 2020 | 1458 | 0.290 |
Why?
|
| Ganglioglioma | 1 | 2006 | 4 | 0.290 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 176 | 0.290 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 619 | 0.290 |
Why?
|
| Treatment Failure | 4 | 2016 | 283 | 0.280 |
Why?
|
| Testicular Neoplasms | 2 | 2019 | 105 | 0.280 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 1202 | 0.280 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 374 | 0.270 |
Why?
|
| Abdomen | 1 | 2006 | 120 | 0.270 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2006 | 109 | 0.270 |
Why?
|
| Postoperative Period | 3 | 2015 | 302 | 0.270 |
Why?
|
| Carcinoma | 2 | 2012 | 436 | 0.270 |
Why?
|
| United States | 7 | 2021 | 6580 | 0.270 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 836 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 261 | 0.240 |
Why?
|
| Probability | 3 | 2012 | 352 | 0.240 |
Why?
|
| Urethral Neoplasms | 2 | 2018 | 10 | 0.240 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 252 | 0.230 |
Why?
|
| Motion | 1 | 2023 | 85 | 0.230 |
Why?
|
| Neoplasm, Residual | 3 | 2012 | 162 | 0.230 |
Why?
|
| Patient Selection | 3 | 2017 | 675 | 0.220 |
Why?
|
| Propensity Score | 2 | 2020 | 132 | 0.220 |
Why?
|
| Ipilimumab | 1 | 2022 | 58 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 86 | 0.210 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 1776 | 0.210 |
Why?
|
| Contrast Media | 2 | 2016 | 1067 | 0.210 |
Why?
|
| Incidence | 2 | 2022 | 1543 | 0.200 |
Why?
|
| Radiation Oncologists | 2 | 2021 | 13 | 0.200 |
Why?
|
| Ticlopidine | 2 | 2012 | 25 | 0.190 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 1054 | 0.190 |
Why?
|
| Radium | 1 | 2020 | 7 | 0.190 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 763 | 0.190 |
Why?
|
| Warfarin | 2 | 2012 | 103 | 0.180 |
Why?
|
| Platelet Count | 1 | 2020 | 92 | 0.180 |
Why?
|
| Internship and Residency | 2 | 2021 | 1011 | 0.180 |
Why?
|
| Radiologic Health | 1 | 2019 | 2 | 0.180 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 18 | 0.170 |
Why?
|
| Sezary Syndrome | 1 | 2019 | 8 | 0.170 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 41 | 0.170 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 23 | 0.170 |
Why?
|
| Depsipeptides | 1 | 2019 | 29 | 0.170 |
Why?
|
| Electrons | 1 | 2019 | 49 | 0.170 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 48 | 0.170 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 49 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2021 | 751 | 0.170 |
Why?
|
| Mitomycin | 2 | 2016 | 29 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 937 | 0.160 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 373 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 164 | 0.160 |
Why?
|
| Proctoscopy | 1 | 2017 | 1 | 0.160 |
Why?
|
| Prostatic Diseases | 1 | 2017 | 3 | 0.160 |
Why?
|
| Digital Rectal Examination | 1 | 2017 | 7 | 0.160 |
Why?
|
| Neoplasms | 1 | 2013 | 2895 | 0.150 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2500 | 0.150 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 111 | 0.150 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 429 | 0.150 |
Why?
|
| Movement | 1 | 2020 | 299 | 0.150 |
Why?
|
| Clinical Competence | 3 | 2021 | 756 | 0.150 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 94 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2022 | 631 | 0.150 |
Why?
|
| Postoperative Care | 1 | 2018 | 221 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 408 | 0.140 |
Why?
|
| Remission Induction | 1 | 2018 | 722 | 0.140 |
Why?
|
| Ilium | 1 | 2016 | 18 | 0.140 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 38 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 164 | 0.140 |
Why?
|
| Camptothecin | 1 | 2017 | 189 | 0.140 |
Why?
|
| Nephrectomy | 1 | 2019 | 290 | 0.140 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.140 |
Why?
|
| Internationality | 1 | 2016 | 69 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 1989 | 0.140 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 2702 | 0.140 |
Why?
|
| Patient Safety | 1 | 2018 | 209 | 0.140 |
Why?
|
| Urology | 1 | 2017 | 110 | 0.140 |
Why?
|
| Neutropenia | 1 | 2016 | 215 | 0.140 |
Why?
|
| Software | 1 | 2020 | 653 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 3 | 2024 | 552 | 0.130 |
Why?
|
| Seminoma | 1 | 2015 | 10 | 0.130 |
Why?
|
| Orchiectomy | 1 | 2015 | 68 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2019 | 426 | 0.130 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2014 | 30 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 898 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 47 | 0.130 |
Why?
|
| Carboplatin | 1 | 2015 | 286 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 546 | 0.120 |
Why?
|
| Health Surveys | 1 | 2014 | 236 | 0.120 |
Why?
|
| Kidney | 1 | 2019 | 1128 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 373 | 0.120 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 32 | 0.110 |
Why?
|
| Radiography | 2 | 2006 | 806 | 0.110 |
Why?
|
| Metalloporphyrins | 1 | 2012 | 26 | 0.110 |
Why?
|
| Enoxaparin | 1 | 2012 | 23 | 0.110 |
Why?
|
| Prevalence | 1 | 2016 | 1210 | 0.110 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2013 | 59 | 0.110 |
Why?
|
| Constriction, Pathologic | 1 | 2013 | 212 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 466 | 0.100 |
Why?
|
| Curriculum | 1 | 2016 | 542 | 0.100 |
Why?
|
| Age Factors | 3 | 2010 | 1828 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2017 | 593 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1015 | 0.100 |
Why?
|
| Students, Medical | 1 | 2016 | 386 | 0.100 |
Why?
|
| Proctitis | 1 | 2010 | 12 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2012 | 440 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 266 | 0.100 |
Why?
|
| Algorithms | 2 | 2019 | 1824 | 0.100 |
Why?
|
| Neck Dissection | 2 | 2008 | 65 | 0.090 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2010 | 49 | 0.090 |
Why?
|
| Genetic Therapy | 1 | 2012 | 343 | 0.090 |
Why?
|
| Seminal Vesicles | 2 | 2016 | 39 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2904 | 0.090 |
Why?
|
| Registries | 3 | 2010 | 701 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 1655 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 102 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2013 | 512 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 685 | 0.080 |
Why?
|
| Urologic Diseases | 1 | 2009 | 45 | 0.080 |
Why?
|
| Thymidine Phosphorylase | 1 | 2008 | 5 | 0.080 |
Why?
|
| Young Adult | 3 | 2019 | 5961 | 0.080 |
Why?
|
| Vitamin B Complex | 1 | 2008 | 21 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 827 | 0.080 |
Why?
|
| Indium Radioisotopes | 1 | 2007 | 10 | 0.080 |
Why?
|
| Pharynx | 1 | 2006 | 45 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 1136 | 0.070 |
Why?
|
| Iodine Radioisotopes | 1 | 2006 | 134 | 0.070 |
Why?
|
| Cisplatin | 2 | 2024 | 612 | 0.070 |
Why?
|
| Chicago | 1 | 2009 | 1378 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 429 | 0.060 |
Why?
|
| Palliative Care | 1 | 2006 | 257 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 70 | 0.060 |
Why?
|
| Disease Management | 2 | 2017 | 315 | 0.060 |
Why?
|
| Digestive System | 1 | 2003 | 42 | 0.060 |
Why?
|
| Physics | 1 | 2021 | 21 | 0.050 |
Why?
|
| Mastectomy | 1 | 2004 | 243 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 167 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2021 | 79 | 0.050 |
Why?
|
| Perception | 1 | 2021 | 168 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2006 | 3612 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 503 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 294 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 107 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 149 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 212 | 0.040 |
Why?
|
| Nitriles | 1 | 2019 | 148 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 175 | 0.040 |
Why?
|
| Inflammation | 1 | 2004 | 922 | 0.040 |
Why?
|
| Benzamides | 1 | 2019 | 229 | 0.040 |
Why?
|
| Aftercare | 1 | 2019 | 85 | 0.040 |
Why?
|
| Kallikreins | 1 | 2017 | 47 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2017 | 80 | 0.040 |
Why?
|
| Efficiency | 1 | 2017 | 38 | 0.040 |
Why?
|
| Pelvis | 1 | 2017 | 94 | 0.040 |
Why?
|
| Radiometry | 1 | 2016 | 53 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2017 | 73 | 0.040 |
Why?
|
| Equipment Design | 1 | 2017 | 405 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 119 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 101 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 156 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 129 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 358 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 812 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 676 | 0.030 |
Why?
|
| Child | 1 | 2006 | 6930 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1696 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 180 | 0.030 |
Why?
|
| Internet | 1 | 2017 | 311 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 225 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 90 | 0.030 |
Why?
|
| Adolescent | 1 | 2006 | 8959 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 1205 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 813 | 0.030 |
Why?
|
| Fatigue | 1 | 2013 | 174 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1471 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 393 | 0.020 |
Why?
|
| Nomograms | 1 | 2007 | 28 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2007 | 225 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1804 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1121 | 0.010 |
Why?
|